Overview
Clients from large and established pharmaceutical companies to small biotech start-ups call upon our multidisciplinary team of attorneys to provide counsel in connection with a wide variety of matters, including:
- Mergers and Acquisitions
- Public and Private Financings
- Licensing, Collaborations and Joint Ventures
- U.S. and China Regulatory
- Government Enforcement
- Securities & Futures Enforcement
- Intellectual Property and Litigation
- Antitrust
Many of our attorneys and professionals hold Ph.D.s in areas that include biochemistry, biomedical sciences, cellular biology, chemistry, molecular biology, genetics, experimental medicine, immunology and pharmacology.
Experience
Our attorneys have comprehensive experience across the biotech and pharmaceutical industries, including:
- Pfizer in its $14 billion acquisition of Medivation Inc., a biopharmaceutical company focused on developing and commercializing small molecules for oncology.
- Shire in its agreement with Baxalta Incorporated to combine the companies for an aggregate consideration of approximately $32 billion. Baxalta, headquartered in Northern Illinois, is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology, and immunology.
- Boehringer Ingelheim in its $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
- Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
- A leading pharmaceutical company in a patent case involving the use of Botox® to treat pain from spinal compression, where the representation included a trial before the PTAB.
- Mersana Therapeutics, a clinical-stage biopharmaceutical company, in connection with its $75 million initial public offering.
- JHL Biotech in a strategic alliance with Sanofi to develop and commercialize biological therapeutics in China and potentially internationally. Under the agreement, Sanofi will invest US$80 million in JHL and make an upfront payment of US$21 million to acquire rights to certain JHL biologics. In addition, JHL will be entitled to receive milestones of up to US$236 million and sales royalties.
- Pacira Pharmaceuticals in First Amendment and APA challenges to FDA’s assertions that the company engaged in “off-label” promotion of its flagship product, a post-surgical analgesic. As a result, FDA agreed to withdraw its warning letter and revise the label to clarify that the challenged claims were permissible.
- Sarepta Therapeutics in its $584 million exclusive license and collaboration agreement with Summit Therapeutics for the European rights to Summit’s utrophin modulator pipeline for the treatment of Duchenne Muscular Dystrophy.
- Pfizer in a joint collaboration with Merck KGaA to develop and commercialize an anti-PD-L1 antibody to treat tumors. Under the terms of the agreement, Merck will receive $850 million upfront and $2 billion in regulatory and commercial milestone payments.
- Zai Lab in its $30 million Series C preferred equity financing round, led by OrbiMed with other new investors Vivo Capital, Cormorant and Rock Springs Capital.
